Publications
291
Citations
2,743
Est. group size
~2
Recurring co-author estimate
Active years
57
Publishing since 1970
Naoki Furuya's research focuses on non-small cell lung cancer (NSCLC), particularly how genetic mutations such as EGFR, ALK, and RET affect treatment response and drug resistance. The work spans clinical trials comparing chemotherapy, immunotherapy, and targeted drugs, as well as laboratory studies of molecular signaling pathways that allow cancer cells to become resistant to targeted therapies. This research aims to help clinicians choose the most effective treatment strategies for different subtypes of lung cancer.
Publication output has grown substantially over the past decade, rising from single digits in 2017 to over 60 publications per year by 2023 and 2025, indicating a strong and increasing rate of research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- AXL–SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers
npj Precision Oncology · 2026
- Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
Journal of Clinical Oncology · 2025
- Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
Lung Cancer · 2025
- Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising‐ <scp>VTE</scp> / <scp>NEJ037</scp> Study
Cancer Medicine · 2025
- Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study
Translational Lung Cancer Research · 2025
- Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure
Targeted Oncology · 2025
- Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)
Radiation Oncology · 2025
- Regimen Selection for Chemoimmunotherapy in Nonsquamous Non–Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study
Clinical Lung Cancer · 2025
- Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study
International Journal of Clinical Oncology · 2025
- Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan
Translational Lung Cancer Research · 2025
- Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Cancer Research Communications · 2025
- Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer
Journal of Thoracic Disease · 2025
- Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression
ESMO Real World Data and Digital Oncology · 2025
- <i>EGFR</i> Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics
Future Oncology · 2025
- Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression
Translational Lung Cancer Research · 2025
- Journal of Clinical Oncology×33
- Annals of Oncology×21
- Journal of Thoracic Oncology×18
- Lung Cancer×12
- Thoracic Cancer×7
- Po‐Lan Su
Medicine · The Ohio State University
- Gregory A. Durm
Medicine · Indiana University
- Erin M. Bertino
Medicine · The Ohio State University
- David P. Carbone
Medicine · The Ohio State University
- Hossein Borghaei
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile